Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Inclusion Criteria: 1. Female and Male patients at least 18 years old referred for clinical suspicion of primary or recurrent BCa who have been advised to undergo TURBT. 2. Patients with a TUR-confirmed diagnosis of NMIBC and candidate for second look and resection (Re-TURBT) according to EAU Guidelines \[6\]. 3. No imaging evidence (i.e., mpMRI/VI-RADS score 1 or 2) of muscle-invasive, locally advanced, or metastatic BCa (i.e., only confirmed CIS, Ta, T1, N0, M0 will be considered eligible). 4. Patients who did or did not receive previous BCG immunotherapy (i.e., BCG naïve and non-naïve patients). 5. Fit to undergo all procedures listed in protocol. 6. Able to provide written informed consent. Exclusion Criteria: 1. Contraindication to TURBT and/or Re-TURBT. 2. Initial TURBT diagnosis of MIBC (i.e., T2) or locally advanced BCa (i.e., T3-T4). 3. Preoperative evidence of metastatic disease (i.e., cN1 - N3 and/or cM1). 4. Visual evidence of low-risk NMIBC (solitary tumor, \< 1 cm) before initial TURBT. 5. Visual evidence of MIBC on preliminary cystoscopy (i.e., non-papillary or sessile mass attached directly by its base without a stalk). 6. TURBT diagnosis of NMIBCs not eligible for Re-TURBT according to EAU Guidelines (i.e., Ta-LG; Ta-HG with detrusor muscle in the specimen; primary CIS) \[6\]. 7. Concomitant Upper tract (kidney or ureteric) tumours on imaging. 8. Contraindication to adjuvant intravesical BCG immunotherapy. 9. Unfit to undergo any procedures listed in protocol.